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ไตเสื่อมระยะที ่3 วิธีการศึกษา: การศกึษาเชงิทดลองชนิดกลุ่มเดยีวแบบวดัผล
ก่อนหลัง โดยเภสัชกรใช้แนวทางฯ ที่ตกลงร่วมกับแพทย์ในการดูแลผู้ป่วย
โรคเบาหวานทีม่ไีตเสือ่มซึง่ควบคมุน้ําตาลในเลอืดไมไ่ด ้30 ราย ตดิตามคา่น้ําตาล
ในเลือดสะสม น้ําตาลหลงัอดอาหาร และค่าการทํางานของไตเป็นระยะเวลา 6 
เดือน ผลการศึกษา: เมื่อจบการศกึษาเดือนที่ 6 ค่าเฉลี่ยน้ําตาลในเลือดสะสม
ของผู้ป่วยเท่ากบัร้อยละ 7.21 ± 0.74 ลดลงจากค่าเริม่ต้น 8.28 ± 0.79 อย่างมี
นัยสําคญัทางสถิติ (P-value < 0.001) ซึ่งเข้าสู่เป้าหมายการรกัษา 19 จาก 30 
ราย (ร้อยละ 63.33) หลงัได้รบัการดูแลจากเภสชักรผู้ป่วยมีความพึงพอใจโดย









Objective: To study the effects of collaborative drug therapy management 
(CDTM) protocol for glycemic control in diabetic patients with stage 3 chronic 
kidney disease (CKD). Methods: In this one- group pre-post study, CDTM 
protocol by the pharmacist was tested in 30 uncontrolled patients with stage 
3 CKD. HbA1C, FPG and renal functions were monitored for 6 months. 
Result: At the end of the study, HbA1C significantly decreased from baseline 
(7. 21 ± 0. 74 to 8. 28 ± 0. 79%, P-value < 0.001). The 19 of 30 patients 
(63.33%) achieved a target of glycemic control. They were strongly satisfied 
with the CDTM care (mean score 4.61 ± 0.36 points). Conclusion: The 
CDTM protocol could improve glycemic control and achieve the target in 
diabetic patients with poor glycemic control and stage 3 CKD. It was highly 
satisfactory.  
Keywords: collaborative drug therapy management, diabetes, renal 







Diabetes has been a major public health problems with an 
increasing trend worldwide.1 More than 50% of diabetes 
patients have poor glycemic control according to their target 
blood glucose.2 Kidney disease is the most frequent 
complication of poor glycemic control.3 About 34% of kidney 
disease is related with diabetes.4 At Phrachomklao Hospital, 
Phetchaburi, Thailand, continuous, poor glycemic control was 
found in 50% of diabetes patients. As a result, rate of the 
progression to stage 3 chronic kidney disease (CKD) has been 
increasing. Medical care for this group of patients has been 
however limited. With a ratio of physicians to patients of 1:75, 
physicians could spend only 3 minutes with each of these 
diabetic patients at the out-patient department. In addition, 
with a constant monthly rotation of physicians, continuity of 
care cannot be achieved. As a result, more patients have poor 
glycemic control.  
With the attempt to achieve a better glycemic control, 
hospitals have tried various interventions. The best method is 
the adjustment of the healthcare team or team change. The 
extension of healthcare team members’ responsibility in 
patient monitoring and therapeutics adjustment has been 
proved to be efficient.5 Collaborative drug therapy 
management (CDTM) between physicians and pharmacists is 
one of such platforms for patient care. CDTM is achieved 
under the agreement between physicians and pharmacists on 
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drug therapy starting with drug therapy initiation, adjustment, 
and continuation under the mutually agreed protocol.6  
In Thailand, studies indicated that CDTM helped 
significantly improve fasting plasma glucose level. 7,8 Patients 
received CDTM had a more frequent drug dosage adjustment 
than those patients receiving the usual care. In Thailand and 
worldwide, most diabetes patients with poor glycemic control 
are involved in clinical inertia9,10 which could lead to more CKD 
progression. CDTM as an intensive treatment modality could 
alleviate such clinical inertia. Since longstanding diabetes is 
usually associated with the massive defects of beta-cells, sole 
diet control with inadequate therapeutic drug dosage 
adjustment may not help the patient achieve their target 
glycemic control and progression rate to CKD is accelerated. 
An early achievement of target glycemic control could help 
decelerate the CKD progression in the long run.    
With the concern on the renal complication in diabetes 
patients with poor glycemic control, the researcher with the 
collaboration with physicians had developed the CDTM-based 
care for drug therapy management in diabetic patients with 
CKD. The ultimate goal was to slow the further CKD 
progression.  This research aimed to examine the effect of the 
CDTM-based care on glycemic control among diabetes 
patients with stage 3 CKD. Patient’s satisfaction toward the 
CDTM-based care provided by pharmacists. Specifically, it 
was hypothesized that (1) the patient’s HbA1C level and 
fasting plasma glucose (FPG) level after receiving CDTM-
based care were lower than those before the care, (2) a higher 
number of patients with HbA1C within target level than that 
before the CDTM-based care, and (3) estimated glomerular 
filtration rate (eGFR) level after receiving CDTM-based care 
was higher or equal to that before the care. Glycemic control 
based on HbA1C was defined as HbA1C < 8.0% for patients 
aged 65 years or older, and < 7.0% for those aged < 65 years.  
In the CDTM-based care, diabetes patients were taken 
care of with the following investigation and management. The 
patients were instructed to fast at least 8 hours before blood 
chemistry investigation. Effectiveness of drugs for lowering 
blood glucose and safety of the drugs were assessed. Dose 
appropriate for the patient’s kidney function was evaluated. 
Dose adjustment and/or drug change were done according to 
the kidney function, drug’s efficacy, safety, and cost. In the 
CDTM-based care, 3 drug therapy adjustments were defined. 
First, the adjustment with all pharmacist’s recommendations 
accepted includes dose adjustment according to the [protocol 
within the maximum dose or continuation of the same drug 
with the maximum dose corresponding to the patient’s kidney 
function. Second, the adjustment with only some pharmacist’s 
recommendations accepted means dose adjustment 
according to the protocol within the maximum dose. Third, the 
pharmacist’s recommendations rejected means drug regimen 
adjustment not according to the protocol such as adjusting 
dose over the maximum dose, or prescribing medications not 
in the protocol. In this research, clinical outcomes included 
HbA1C level, FPG after at least 8 hours fasting, eGFR and 
serum creatinine (SCr) level at months 3 and 6 (as dependent 





In this one-group pre-post study, benefits of collaboration 
between physicians and pharmacists on the CDTM-based 
care we examined by comparing the outcomes in the patients 
at months 0, 3 and 6 after receiving the care. The study was 
conducted at diabetes clinic of Phrachomklao Hospital, 
Petchaburi province, Thailand, from August 1, 2018 to July 31, 
2019.  
In the exploratory study, sample size was not estimated. 
Based on the concept of project testing, a minimum of 30 
subjects were required.11 In the actual study setting, with a 
laboratory test one day before the screening required, a very 
small number of patients could meet the inclusion and 
exclusion criteria. Therefore, the researcher included eligible 
patients resulting in 34 participants within the 5-month period. 
To be eligible, the patients had to be 35 years or older with 
the diagnosis of stage 3 CKD and type 2 diabetes. They also 
had to have an HbA1C level of 7% or higher and an FPG level 
of 150 mg/dl or higher. Those who were pregnant, had cancer 
or severe infection (i.e., AIDs, tuberculosis, etc), used insulin, 
lost to follow-up, referred to other healthcare setting, or had 
essential laboratory investigation results lost were excluded.  
  
Research instruments  
Two instruments were used in this study, CDTM-based 
care protocol and satisfaction questionnaire. The two 
instruments were developed by the researcher and tested for 
content validity by 3 experts (2 specialists in internal medicine 
and one pharmacist). The instruments were found to have an 
acceptable content validity with the Item Objective 
Congruence Index (IOC) of 0.83 by average.  
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CDTM-based care protocol  
The protocol laid out the collaboration between physicians 
and pharmacists for the care of diabetes patients with stage 3 
CKD. The protocol consisted of (1) preparation of the patients 
to the CDTM-based care (IOC = 0.86), (2) assessment of the 
efficacy of oral glucose lowering drugs (IOC = 0.87), (3) 
assessment of the safety of oral glucose lowering drugs (IOC 
= 0.95), (4) assessment of the dose of oral glucose lowering 
drugs according to kidney function (IOC = 0.67), (5) guidance 
for adjusting drugs or drug doses based on comparative 
efficiency, safety and cost (IOC = 0.67), (6) steps for adjusting 
doses of oral glucose lowering drugs according to kidney 
function (IOC = 0.67), (7) therapeutic monitoring strategy (IOC 
= 0.67). This protocol covered only 4 oral glucose lowering 
drugs (i.e., metformin, glipizide, pioglitazone and sitagliptin), 
insulin injection excluded. In performing the collaborative task, 
pharmacists communicated with physicians verbally to discuss 
about dose adjustment, opinions and approval for adjustment 
according to the protocol.  
  
Satisfaction questionnaire   
The questionnaire asked the patients about their 
satisfaction toward the CDTM-based care provide by 
pharmacists in various aspects including the promptness of 
the service, pharmacist service quality, therapeutic outcome 
quality, facilities and place. The questionnaire had a high 
content validity with an IOC of 1.00  
 
Research procedure  
Steps in providing the CDTM-based care were as follows. 
The researcher screen patients in advance based on 
laboratory investigation results (HbA1C, FPG, eGFR, and 
serum creatinine). These laboratory investigation was done 
one day before the usual follow-up appointment date. On the 
next day, the patients registered at the diabetes clinic as 
appointed and their weight, height were, and vital signs were 
measured and history of illness was examined by the nurse.   
In the meeting with the pharmacist, medications 
reconciliation was performed by the pharmacist to check for 
any problems or inappropriateness in medications obtained 
from the hospital or other healthcare settings. The pharmacist 
reviewed medication use, evaluated patient’s compliance on 
drug use, identified drug-related problems, and identified any 
factors interfering blood glucose level. Based on the 
information obtained, the pharmacist determined goal of drug 
therapy and planned therapeutic management accordingly as 
follows. The pharmacist reviewed HbA1C, FPG, maximum 
dose, and eGFR, compared efficacy, safety and cost of oral 
glucose lowering drugs. The pharmacist then evaluated the 
efficacy of the oral glucose lowering drugs the patient was 
using, accompanied with HbA1C level as guided by the 
protocol. Dose adjustment was done as guided by the protocol 
with drugs available in the hospital (metformin, glipizide, 
pioglitazone and sitagliptin). The pharmacist evaluated safety 
profile of the drugs the patient was using such as 
hypoglycemia, edema, etc. Finally, the pharmacist 
summarized drug therapeutic plan to present to the physician. 
The pharmacist reported the assessment to the physician in 
person. The physician followed the protocol and discussion 
with pharmacist about the patient evaluation and therapeutic 
plan. Opinions were exchanged and the mutual decision on 
therapeutic management was planned. Finally, the pharmacist 
planned laboratory investigation appointment, follow-up 
appointment, dispensing medications and provided medication 
use advice to the patient.  
Data for research analysis were collected at the first visit 
with the initiation of CDTM-based care (month 0). Clinical 
outcomes data were collected at months 0, 3 and 6; while 
satisfaction data were collected at month 6. All other 
information in the usual care was collected at all visits 
between months 0 and 6, if any.  
  
Human right protection 
This study was approved by the Ethics Committee on 
Human Study of Naresuan University (IRB No. 259/60) and of 
Pharchomklao Hospital (Approval No. 13/2560). All patients 
were informed about the study and asked for permission to 
use their data for analysis. They were also informed about the 
voluntary nature of the study and their refusal to participate 
would not affect the care they received. Findings were 
presented as summary results.  
 
Data analysis  
Demographic and general clinical data of the patients were 
presented with descriptive statistics including mean with 
standard deviation and frequency with percentage. The 
changes of clinical outcomes which were continuous variables 
(HbA1C, FPG, eGFR and serum creatinine level) from month 
0 to months 3 and 6, were tested with one-way repeated 
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ANOVA for normally distributed data and Friedman’s test for 
non-normally distributed data. Statistical significance for all 
tests was set at a type I error of 5% (P-value < 0.05). Patient’s 
satisfaction toward CDTM-based care was presented as mean 
with standard deviation. In addition to outcomes of the study 
objectives, acceptance of the physician toward 
recommendation on drug adjustment according to the protocol 
was presented as frequency with percentage. All statistical 
analyses were carried out using statistical software SPSS 




Of a total of 34 patients, four patients were excluded; one 
was suspected to have lung cancer, and three were with 
incomplete essential information. Of the 30 remaining patients, 
there were 146 visits, of which 116 were follow-up visits. There 
were slightly women (53.3%) than men. They were of 65 years 
of age by average. They were numbers of patients with stage 
3a and 3b CKD equally. Their eGFR was 45.84 ± 9.4 
ml/min/1.73 m2 and HbA1C level of 8.3 ± 0.8% by average 
(Table 1).  
 
 Table 1   General characteristics of participants (N = 30).  
Characteristics N % 
Gender   
Male 14 46.67 
Female 16 53.33 
Age, yrs, (mean ± SD) 64 ± 8.9 
Underlying disease   
Diabetes and dyslipidemia 2 6.67 
Diabetes, hypertension, and dyslipidemia  28 93.33 
Duration of diabetes, yrs, (mean ± SD)  10.7 ± 4.3 
Duration of CKD, yrs, (mean ± SD) 3.77 ± 2.0 
Oral glucose lowering drugs   
Glipizide 1 3.33 
Metformin + Glipizide  16 53.34 
Glipizide + Pioglitazone 4 13.33 
Metformin + Glipizide + Pioglitazone 9 30.00 
Stage of CKD   
3a 15 50.00 
3b 15 50.00 
eGFR, ml/min/1.73 m2, (mean ± SD)  45.84 ± 9.4 
SCr, mg/dL, (mean ± SD)   1.45 ± 0.32 
HbA1C, %, (mean ± SD)   8.3 ± 0.8 
FPG, mg/dL, (mean ± SD) 186.7 ± 35.7 
  
Note: eGFR = estimated glomerular filtration rate; SCr = serum creatinine level; FPG = fasting plasma glucose 
level  
 
Dose adjustment of oral glucose lowering drugs 
according to kidney function  
Based on the drug use evaluation at 146 visits, the over 
maximum dose of metformin was found 11 times. Pharmacists 
discussed with the physician to reduce the dose according to 
the kidney function to prevent lactic acidosis. Physicians 
agreed with all 11 incidents. Physicians also increased the 
dose of at least one oral glucose lowering drug according to 
the protocol. Drug with the most number of dose increase was 
glipizide (12 times) and pioglitazone (11 times). These 
increases were because metformin reached its maximum 
dose.  
 
Acceptance of physicians toward adjustments 
according to collaboration between physicians and 
pharmacists  
Of all 116 drug dose and frequency adjustment 
recommendations, the majority were all and partial 
recommendations combined (88 of 116 recommendations, or 
75.86%) while the rest 28 recommendations (24.14%) were 
rejected (Table 2).  
 
 Table 2  Acceptance of physicians on pharmacist’s 
recommendations on dose adjustment according to CDTM-
based care protocol (116 recommendations).  
Acceptance categories N % 
All pharmacist’s recommendations accepted: adjusting dose and 
frequency according to the protocol; continuing the under-





Only some pharmacist’s recommendations accepted: adjusting 
dose and frequency according to the protocol with under-
maximum dose 
10 8.62 
Pharmacist’s recommendations rejected: no dose or frequency 
adjustment according to the protocol 
28 24.14 
Total 116 100.00 
 
Safety monitoring outcomes  
Based on the 116 visits, adverse drug events were found 
2 time with a triple therapy (metformin + glipizide + 
pioglitazone), one non-severe hypoglycemia corrected with 
decreasing a dose of glipizide and another edema with 
pioglitazone corrected by discontinuation of the drug and 
increasing another drug. The decrease of eGFR to be less 
than 30 ml/min/1.73m2 or more than 5 ml/min/1.73m2 which 
was an alarm sign of metformin use were found 8 times and 
incidents were reported to physicians for further proper dose 
adjustment.  
 
Glycemic control outcomes  
Based on the acceptance of 88 out of 116 dose 
adjustment recommendations (75.86%), mean HbA1C and 
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FPG at months 3 and 6 were lower than that at month 0 with 
statistical significance (Table 3). At month 6, there were 18 
out of 25 patients (72.00%) achieving glycemic control based 
on HbA1C within target and their recommendations were 
completely and partially accepted by physicians. On the other 
hand, among 5 patients with their recommendations rejected 
by physicians, only 1 of them achieve glycemic control target 
(20.00%) (Table 4).  
 
 Table 3  Glycemic controls outcomes as HbA1C and fasting 
plasma glucose (FPG) at months 0, 3 and 6 based on the 
acceptance of 88 out of 116 dose adjustment recommendations.  
Glycemic control 
outcomes 
Mean ± SD 
P-value 
Month 0 Month 3 Month 6 
HbA1C (%) 8.28 ± 0.79 7.43 ± 0.76a 7.21 ± 0.74b,c < 0.001* 
FPG (mg/dL) 186.70 ± 35.7 132.70 ± 30.2d 122.43 ± 18.1e,f < 0.001† 
  
* Overall one-way repeated ANOVA test.  
a One-way repeated ANOVA pair-wise comparison between month 0 and month 3 (P-value < 0.001).  
b One-way repeated ANOVA pair-wise comparison between month 0 and month 6 (P-value < 0.001). 
c One-way repeated ANOVA pair-wise comparison between month 3 and month 6 (P-value = 0.014).  
† Friedman test for overall comparison.  
d Wilcoxon signed ranks test for pair-wise comparison between month 0 and month 3 (P-value < 0.001).  
e Wilcoxon signed ranks test for pair-wise comparison between month 0 and month 6 (P-value < 0.001). 
c Wilcoxon signed ranks test for pair-wise comparison between month 3 and month 6 (P-value = 0.075).  
 
 Table 4  Proportions of patients with achieving glycemic 
control based on HbA1C within target at month 6 (Number of 
patients = 30).*  
Glycemic control based 
on HbA1C within target at 
month 6 
Number of patients (%) 
All and some 
recommendations accepted 
(n = 25) 
Recommendations 
rejected 
(n = 5)  
Target achieved* 18 (72.00) 1 (20.00) 
Target not achieved 7 (28.00) 4 (80.00) 
รวม 25 (100.00) 5 (100.00) 
  
* Glycemic control based on HbA1C: < 8.0% for patients aged 65 years or older, and < 7.0% for those aged < 65 
years.  
Kidney function outcomes  
Levels of both eGFR and SCr at month 0, 3 and 6 were 
comparable (Table 5).  
 
 Table 5  Kidney function outcomes at months 0, 3 and 6 
(Number of patients = 30).  
Kidney function 
Mean ± SD (median)  
P-value 
Month 0 Month 3 Month 6 
eGFR (ml/min/1.73 
m2) 
45.84 ± 9.4 
(46.68) 
47.96 ± 11.0 
(47.04) 
46.88 ± 11.3 
(44.60) 
0.655* 
SCr (mg/dL)  
 
1.45 ± 0.3 
(1.41) 
1.41 ± 0.4 
(1.39) 




 * Friedman’s test; † one-way repeated ANOVA.  
 
Satisfaction of the patients toward CDTM-based care 
by the pharmacist   
Overall, the patients were highly satisfied with the CDTM-
based care (mean score of 4.61 ± 0.36 points). The most 
satisfactory aspect was the service rendered by the 
pharmacist (mean score of 4.79 ± 0.37 points), followed by 
therapeutic outcomes of the service (mean score of 4.68 ± 
0.38 points). 
 
Discussions and Conclusion 
Collaborative drug therapy management (CDTM) based 
care was approved by the physicians with a 75.86% of 
recommendations accepted. CDTM-based care helped 
improve glycemic control based on HbA1C and FPG 
significantly, which was evident at 3 and 6 month among 
diabetes patients with stage 3 CKD with poor glycemic control 
(P-value < 0.001). Since HbA1C decreased by 1% in this 
study, CDTM-based care could be beneficial in slowing 
progression of microvascular complications by 37%.12  
The benefit on glycemic control of the CDTM-based care 
in this study was consistent with a trial examining CDTM-
based care as a part of care for diabetes patients with poor 
glycemic control.7 In that study, HbA1C at 1 year in patients 
receiving the CDTM-based care provided by the pharmacist 
decreased by 2% while those using usual care only had a 
decrease of 0.8%, resulting in a 1.2% difference with statistical 
significance (P-value < 0.01). However, patients in that study 
did not have CKD, study duration was longer, control group 
was included, and other care modalities to promote 
compliance and self-care were used in addition to the CDTM-
based care and usual care. Yet, their study had the results 
comparable to ours.  
Our finding was also consistent with a study examining the 
effect of CDTM-based care by pharmacists in type 2 diabetic 
patients.8 They also found that in the experimental group, 
HbA1C decreased from 8.3% to 7.5% at 6 months (P-value < 
0.001) and FPG decreased from 151.6 mg/dL to 128.3 mg/dL 
(P-value = 0.006). The study employed the proper control 
group.  
Our study was comparable with a study of multidisciplinary 
care for CKD patients where pharmacists reviewed 
therapeutic management of the physician and laboratory 
results, identified drug related problems, recommended drug 
selection, dose adjustment according to kidney function, and 
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monitored efficacy and safety of drug therapy. 13 Pharmacists 
were allowed to discuss with and provide information to the 
physicians.13 After 1 year, HbA1C decreased from 8.80% to 
7.40% (P-value < 0.001). their finding was consistent with ours 
where HbA1C decreased from 8.28 ± 0.79% to 7.21 ± 0.74% 
(a mean decrease of 1%) and FPG decreased from 186.70 ± 
35.7 mg/dL to 122.43 ± 18.1 mg/dL. These similarities could 
be due to similar characteristics of the patients of the two 
studies such as the elderly patients, risk factors of CKD 
(diabetes, hypertension, and HbA1C prior study). Differences 
between the two studies were that duration of diabetes and 
CKD in our study was longer, only stage 3 CKD patients were 
included in our study, the protocol was always used to adjust 
the dose of oral glucose lowering drugs according to the FPG 
in our study which could result in a 1% decrease of HbA1C 
within 6 months which was faster than the other study. 
However, in our study, eGFR and serum creatinine before and 
after the intervention were comparable (P-value =0.655 and 
0.984, respectively).  
The unchanged of these kidney function outcomes could 
be due to the patient’s old age. Their age at the start of the 
study was 64 ± 8.9 years, duration of diabetes and 
hypertension of at least 5 years, duration of CKD of 3.77 ± 2.0 
years, and a high proportion of macroalbuminuria (urinary 
albumin of more than 300 mg/gm) (56.7%). With a relatively 
duration of diabetes and a macroalbuminuria in these patients, 
their kidney moght not be changed in a short period of time.14  
In addition to glycemic control to achieve the target, other 
factors to slow CKD progression in type 2 diabetic patients 
included limited consumption of salty food and limited 
consumption of protein of 0.6 – 0.8 gm/kg body weight in stage 
3 CKD patients which could reduce the urinary protein. Salt 
should be limited to less than 2 gm per day. Smoking, holding 
urination, enforcing factors and encouragement from close 
individuals affect self-management in slowing CKD 
progression.15 In our study, participants were provided with 
advice on food from nutritionist to confirm comparable 
knowledge about proper food consumption which could 
reduce variability about food consumption. One of the 
limitations in this study was that most participants were 
inconvenient to record food consumed and activities 
performed daily for the pharmacist to review. This could be 
due to their poor eyesight and living alone.  
CDTM-based care with collaboration of physicians and 
pharmacists with the use of mutually agreed protocol helped 
the patients in adjustment of dose and frequency of oral 
glucose lowering drugs to achieve glycemic control. It also 
helped achieve the dose not exceeding the maximum dose, 
not overload the kidney function, to reduce the risk of adverse 
effects of the drugs excreted through kidney and accumulation 
such as metformin. It also reduced the clinical inertia resulting 
in more patients receiving dose adjustment according to the 
protocol. Proportion of patients achieving glycemic control was 
higher among those their drug doses were adjusted than those 
whose were not. The protocol could help adjust metformin 
dose according to the protocol so that adverse effect of the 
drug could be avoided.  
This study had certain limitations. Small sample size 
limited the confidence in the results precision. This was 
because diabetic patients with stage 3 CKD are those with a 
long duration of diabetes and usually need insulin injection 
which made them ineligible for the study. The protocol did not 
have adjustment for insulin because it is a high-alert drug. A 
relative short duration of study (6 months) did not allow for 
sustainable and/or long-term effects of the care especially 
kidney function outcomes. Future study with longer study 
period and larger sample size should be conducted. Insulin 
should be incorporated into the protocol so that more patients 
with advanced diabetes could be included.    
The protocol tested in our study could be applied in the 
care of type 2 diabetic patients with poor glycemic control and 
stage 3 CKD, without any others disorders or complications. 
The care should be conducted with multidisciplinary team for 
continuous patient care. Users should understand the protocol 
thoroughly especially on the adjustment on dose and 
frequency of 4 oral glucose lowering drugs including metformin, 
glipizide, pioglitazone and sitagliptin. All conducts should be 
mutually agreed by all professionals involving in the care of 
diabetic patients.  
In conclusion, CDTM-based care with the collaboration of 
physicians and pharmacists for type 2 diabetic patients with 
poor glycemic control and stage 3 CKD resulted in a decrease 
in HbA1C and FPG to the target, while kidney function did not 
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